AU Patent

AU2024238367A1 — Method for treating l-dopa-induced dyskinesia using befiradol

Assigned to Neurolixis Inc · Expires 2025-10-09 · 1y expired

What this patent protects

The disclosure provides a method for treating for treating L-DOPA-induced dyskinesia in a patient in need thereof comprising daily administering to the patient a therapeutically effective daily dosage of L-DOPA and befiradol or a pharmaceutically acceptable salt thereof.

USPTO Abstract

The disclosure provides a method for treating for treating L-DOPA-induced dyskinesia in a patient in need thereof comprising daily administering to the patient a therapeutically effective daily dosage of L-DOPA and befiradol or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

gepirone-hydrochloride (GEPIRONE HYDROCHLORIDE)

Patent Metadata

Patent number: AU2024238367A1
Jurisdiction: AU
Classification: —
Expires: 2025-10-09
Drug substance claim: No
Drug product claim: No
Assignee: Neurolixis Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.